Pfizer Highlights Launches, Late-State Pipeline To Distract From Sluggish Earnings
This article was originally published in The Pink Sheet Daily
CEO Ian Read admitted tax inversion remains an attractive potential deal-driver for now, though he declined to offer much insight into the company’s near-term M&A strategy.
You may also be interested in...
Pfizer isn’t considered one of the frontrunners in the immuno-oncology race, but R&D President Mikael Dolsten declares the company, with five agents in the clinic in 2015, will be a force in the therapeutic area.
In this episode, HBW Insight speaks to Heiko Schipper about the Global Self-Care Federation's recently published Self-Care Readiness Index.
Early COVID-19 therapies including Gilead’s remdesivir, China-plus procurement policies, vaccine partnerships and a dovish stance by the central bank led to returns on India biotech and healthcare funds outperforming global returns. Meanwhile, funding for e-pharmacies and online consulting firms gathered pace.